KRAS and neoplasm: Since the K-ras 4A/4B ratio is reduced in primary CRC tumours [12] the altered ratio in cell lines, including those that lack K-ras activating mutations, is more likely to be symptomatic of the tumours from which they were derived rather than an in vitro artefact of the growth conditions.